title: Inhibitory effect of a spicamycin derivative, KRN5500, on the growth of hepatic metastasis of human colon cancer-producing tissue polypeptide antigen.
abstract: The inhibitory effect of KRN5500, a spicamycin derivative, on the growth of hepatic metastasis of the tissue polypeptide antigen (TPA)-producing human colon cancer COL-1 was examined in severe combined immunodeficient (SCID) mice. Prior to this chemotherapeutic study, we confirmed the high correlation coefficient (r = 0.86, P < 0.01) between plasma TPA levels in athymic nude mice bearing COL-1 and tumor volume. In the chemotherapy of experimental hepatic metastasis induced by intrasplenic injection of COL-1 cells, KRN5500 at 12 mg/kg per day was administered i.v. three times at 4-day intervals. From the start of chemotherapy (day 1), plasma TPA levels in the mice were significantly decreased from 8332 U/l to a minimum of 494 U/l on day 16 and were within the range for intact SCID mice (409-634 U/l). The mean tumor weight was 4.87 g in the liver of untreated mice on day 19 and 0.74 g, in the liver of KRN5500-treated mice, a significant difference, representing a tumor growth inhibition rate of 85%. These results suggest the usefulness of TPA as a tumor marker in an experimental xenograft model. The chemotherapeutic efficacy of KRN5500 against experimental hepatic metastasis indicates that it may be a useful drug for the treatment of patients with hepatic metastases of colon cancer.
authors.affiliation: Pharmaceutical Research Laboratory, Kirin Brewery Co. Ltd., Gunma, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kamishohara
authors.forename: H
authors.initials: H
authors.lastname: Kawai
authors.forename: T
authors.initials: T
authors.lastname: Sakai
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: T
authors.initials: T
authors.lastname: Tsuruo
authors.forename: N
authors.initials: N
authors.lastname: Otake
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000556:secondary*; D051379:Mice; D016513:Mice, SCID; D009929:Organ Size; D011684:Purine Nucleosides / Q000737:chemistry / Q000627:therapeutic use; D019396:Tissue Polypeptide Antigen / Q000097:blood / Q000187:drug effects*
chemical_list: D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D011684:Purine Nucleosides; D019396:Tissue Polypeptide Antigen; C092296:KRN 5500